Targeting Genes and Cells in the Progression to Heart Failure

Motoki Sato, Stephen J. Fuller, Roger J. Hajjar, Sian E. Harding

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


The limited success of pharmacologic treatment to reverse the progression of heart failure has let to an exploration of new therapeutic strategies. Gene transfer using viral vectors is successful in restoring function in isolated human ventricular myocytes and animal models, with Ca2+ halding, β-adrenoceptor signaling, and apoptosis as promising targets. Cell transfer to repair damaged myocardium using autologous bone marrow stem cells or skeletal myoblasts is already under clinical evaluation, and such sources as embryonic stem cells are being developed. Common problems must be overcome, such as optimal methods for delivery and the prevention of arrhythmias, so that experiences in the gene and cell transfer fields are likely to provide complementary information during the progression toward an effective therapy.

Original languageEnglish
Pages (from-to)287-301
Number of pages15
JournalHeart Failure Clinics
Issue number2
StatePublished - Jul 2005
Externally publishedYes


Dive into the research topics of 'Targeting Genes and Cells in the Progression to Heart Failure'. Together they form a unique fingerprint.

Cite this